NCT03949049 Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
| NCT ID | NCT03949049 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | Neonatal Hypoxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2019-02-01 |
| Primary Completion | 2029-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 40 participants in total. It began in 2019-02-01 with a primary completion date of 2029-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial
Eligibility Criteria
Inclusion Criteria: * neonates with hypoxia. Exclusion Criteria: * hypoxic ischemic encephalopathy
Contact & Investigator
Abeer Salamah, Lecturer
PRINCIPAL INVESTIGATOR
Pediatrics department - Kafr-Elsheikh university
Frequently Asked Questions
Who can join the NCT03949049 clinical trial?
This trial is open to participants of all sexes, up to 1 Month, studying Neonatal Hypoxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03949049 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 40 participants.
Is NCT03949049 currently recruiting?
Yes, NCT03949049 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT03949049 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT03949049 clinical trial?
NCT03949049 is sponsored by Sherief Abd-Elsalam. The principal investigator is Abeer Salamah, Lecturer at Pediatrics department - Kafr-Elsheikh university. The trial plans to enroll 40 participants.